Here are five recent research findings:
- Among patients with Type 2 diabetes, GLP-1 medications reduced major adverse cardiovascular events by 13% when compared to a placebo.
- Tirzepatide, the active ingredient in Eli Lilly’s GLP-1 medications Mounjaro and Zepbound, reduced the risk of heart failure by 46% and the risk of both heart failure or cardiovascular death by 38% among individuals with obesity.
- Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death and an 84% lower risk of heart attack compared to patients who did not take either medication.
- The death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8% and the heart attack rate was 1.5%, compared to 54% and 6.1%, respectively, for patients who did not take either medication.
- Semaglutide, the active ingredient in Novo Nordisk’s GLP-1 medications Ozempic and Wegovy, reduced annual healthcare costs by $7,502 for patients with overweight or obesity, and by $9,276 for patients with heart failure or atherosclerotic cardiovascular disease.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
